MAMariliina Arjama

Mariliina Arjama

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Mariliina Arjama has a total of 54 co-authors. Here are the top co-authors by number of shared publications:

  • Astrid Murumägi

    Institute for Molecular Medicine Finland (FIMM), Helsinki Institute for Life Sciences (HiLIFE), University of Helsinki, Helsinki, Finland

    4 shared publications
  • Olli Kallioniemi

    Institute for Molecular Medicine Finland (FIMM), Helsinki Institute for Life Sciences (HiLIFE), University of Helsinki, Helsinki, Finland; iCAN Digital Precision Cancer Medicine Flagship, University of Helsinki, Helsinki, Finland; Science for Life Laboratory (SciLifeLab), Department of Oncology and Pathology, Karolinska Institutet, Solna, Sweden

    4 shared publications
  • Ralf Bützow

    Department of Pathology, University of Helsinki and Helsinki University Central Hospital, Helsinki, Finland

    3 shared publications
  • Akira Hirasawa

    Department of Obstetrics & Gynecology, Keio University School of Medicine, Keio, Japan

    2 shared publications
  • Daniela Ungureanu

    Applied Tumor Genomics, Research Programs Unit, Faculty of Medicine and Health Sciences, University of Helsinki, Finland and Tampere University, Tampere, Finland

    2 shared publications
  • Michaela Feodoroff

    Institute for Molecular Medicine Finland-FIMM, Helsinki Institute for Life Sciences -HiLIFE, University of Helsinki, Finland

    2 shared publications

Latest Publications

  • Open Access

    Site-Dependent Decoupling of Drug-Biomarker Associations in Clear Cell Renal Cell Carcinoma Revealed by Functional Profiling of Patient-Derived Cell Models

    by Michaela Feodoroff, Tamara J. Luck, Romika Kumari, Minttu Polso, Patrick Penttilä, Minna Malmstedt, Piia Mikkonen, Lauren J. Gerber, Ruusu Merivirta, Mariliina Arjama, et al.

    Clear cell renal cell carcinoma (ccRCC) frequently exhibits primary and acquired resistance to standard-of-care therapies, underscoring the need for improved strategies to predict therapeutic response and prioritize patient-specific treatments. Although recent multi-omic and single-cell studies have provided insight into the molecular landscape of ccRCC, molecular alterations alone incompletely predict drug sensitivity. We prospectively profiled tumors from 28 patients with localized and metastatic ccRCC by integrating molecular characterization, functional drug sensitivity and resistance testing in patient-derived cell models, and longitudinal clinical data. Although genomic biomarkers suggested potentially actionable therapies in 27/28 patients, functional testing revealed discordance between genomic actionability and ex vivo drug sensitivity, whereas linear mixed-effects modelling uncovered 16 novel copy-number-based features associated with sensitivity to 11 drugs. Genotype-drug response associations were largely preserved between primary tumors and vena cava thrombi but frequently disrupted in distant metastases. Integrating functional drug testing with multi-omic profiling reveals vulnerabilities not apparent from genomic data alone, refines therapeutic actionability, captures interpatient and intersite heterogeneity in ccRCC, and provides a scalable framework for individualized treatment prioritization.


  • Open Access

    Protocol for 3D drug sensitivity and resistance testing of patient-derived cancer cells in 384-well plates

    by Michaela Feodoroff, Piia Mikkonen, Mariliina Arjama, Astrid Murumägi, Olli Kallioniemi, Swapnil Potdar, Laura Turunen, Vilja Pietiäinen


  • Open Access

    STRN-ALK rearranged pediatric malignant peritoneal mesothelioma – Functional testing of 527 cancer drugs in patient-derived cancer cells

    by Astrid Murumägi, Daniela Ungureanu, Mariliina Arjama, Ralf Bützow, Jouko Lohi, Hannu Sariola, Jukka Kanerva, Minna Koskenvuo, Olli Kallioniemi


  • Abstract 2945: Clinical implementation of precision systems oncology in the treatment of ovarian cancer based on ex-vivo drug testing and molecular profiling

    by Astrid Murumägi, Daniela Ungureanu, Suleiman Khan, Akira Hirasawa, Mariliina Arjama, Katja Välimäki, Piia Mikkonen, Wilhelmiina Niininen, Ashwini Kumar, Samuli Eldfors, et al.

    Ovarian cancer (OC) is difficult to treat and has a high mortality rate. There is a strong need for new therapies, but OC is often not the main indication for drug development activities. Hence, here we explored systematic drug repurposing based on clues from ex-vivo testing of human OC patient cells. We established patient-derived cancer cell (PDCs) cultures using ascites or tumor tissue from serous OC patients and applied them to ex vivo Drug Sensitivity and Resistance Testing (DSRT) with a panel of 528 approved and investigational oncology drugs. The representativity of the PDCs was confirmed by genomic and phenotypic profiling in comparison to the original tumor sample. Both 2D and 3D culture conditions were applied and compared for their drug responses. 9 PDCs and 11 high-grade serous OC cell lines were examined. High grade serous OC (HGSOC, 6 cases) with TP53 mutation and CCNE1, CCNE1/KRAS or MYC/KRAS amplifications showed highly resistant drug response profiles, which reflects the clinical challenges in treating this OC subtype. Some HGSOC PDCs showed vulnerability to SMAC mimetics, inhibitors of Apoptosis Protein Antagonists, (e.g. birinapant) and to prexasertib, a checkpoint kinase 1 and 2 inhibitor. In contrast, low-grade serous OC (LGSOC, 3 cases) showed subtype-specific sensitivity to several kinase inhibitors, including EGFR/Her2, MEK, mTOR and PI3K inhibitors. In a metastatic LGSOC patient, RNA-sequencing revealed a CLU-NRG1 fusion gene, which creates an autocrine activation loop of the ErbB family of receptor kinases. DSRT assay confirmed a strong sensitivity of the PDCs ex-vivo to dual-kinase inhibitors, including afatinib. Based on these data, the patient has received approved kinase inhibitors, including afatinib monotherapy followed by a combination of herceptin and pertuzumab. This strategy has managed to keep the disease in control for over 3 years as measured by clinical criteria, including imaging and serum CA125 antigen levels. In conclusion, systems precision cancer medicine with PDCs could provide a valuable approach to reveal patient-specific drug efficacies that can be translated to the clinic in real-time. Citation Format: Astrid Murumägi, Daniela Ungureanu, Suleiman Khan, Akira Hirasawa, Mariliina Arjama, Katja Välimäki, Piia Mikkonen, Wilhelmiina Niininen, Ashwini Kumar, Samuli Eldfors, Teijo Pellinen, Vilja Pietiäinen, Andrus Mägi, Riitta Koivisto-Korander, Johanna Tapper, Mikko Loukovaara, Tero Aittokallio, Ralf Bützow, Olli Kallioniemi. Clinical implementation of precision systems oncology in the treatment of ovarian cancer based on ex-vivo drug testing and molecular profiling [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2019; 2019 Mar 29-Apr 3; Atlanta, GA. Philadelphia (PA): AACR; Cancer Res 2019;79(13 Suppl):Abstract nr 2945.

  • Abstract 3122: Pharmacogenomic profiling to identify novel therapeutic strategies in colorectal cancer

    by Jarle Bruun, Peter W. Eide, Kushtrim Kryeziu, Anita Sveen, Astrid Murumägi, Matthias Kolberg, Mariliina Arjama, Olli Kallioniemi, Ragnhild A. Lothe

    Colorectal cancer (CRC) is amongst the most frequent cancers worldwide and the fourth most common cause of cancer mortality. Surgery is the standard treatment of care, while chemotherapy and/or radiotherapy are offered to subgroups of patients according to disease stage. Current guidelines do not have sufficient accuracy to identify chemotherapy responders, resulting in under- or overtreatment of many patients.To discover novel therapeutic strategies for CRC we performed a high-throughput drug screen containing 461 approved and preclinical drugs on a representative panel of 42 CRC cell lines. Integrative pharmacogenomic profiles were explored by matching data from gene expression, exome sequencing, copy number and reverse-phase protein arrays. These analyses identified defined molecular subgroups sensitive to targeted drugs like Inhibitors of EGFR, IGF-1R and downstream signaling mediators like B-Raf, MEK, PI3K/AKT, as well as inhibitors of aurora mitotic kinases, heat shock protein 90 and p53. Additionally, a correlation between microsatellite instability and sensitivity against topoisomerase-I inhibitors was found. Comparison of the most sensitive and the most resistant cell models against HSP90 inhibitors indicated that drug sensitivity does not depend on target expression but is likely attributed to the cell line-specific expression of client proteins. Real-time cell analyses measured with the xCELLigence system demonstrated a strong impact on cell proliferation but not on the migration of HSP90-sensitive cells treated with HSP90 inhibitors as compared to resistant cells. These integrative analyses have unraveled pharmacogenomic relationships that if validated in in vivo model systems, might be used to stratify patients for therapeutic intervention in biomarker guided clinical trials. Citation Format: Jarle Bruun, Peter W. Eide, Kushtrim Kryeziu, Anita Sveen, Astrid Murumägi, Matthias Kolberg, Mariliina Arjama, Olli Kallioniemi, Ragnhild A. Lothe. Pharmacogenomic profiling to identify novel therapeutic strategies in colorectal cancer [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2017; 2017 Apr 1-5; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2017;77(13 Suppl):Abstract nr 3122. doi:10.1158/1538-7445.AM2017-3122

  • Abstract 410: Identifying ovarian cancer specific targeted drugs using high-throughput drug sensitivity profiles of primary cancer cells

    by Astrid Murumägi, Akira Hirasawa, Suleiman Khan, Daniela Ungureanu, Mariliina Arjama, Teijo Pellinen, Samuli Eldfors, Riitta Koivisto-Korander, Arto Leminen, Ralf Bützow, et al.

    Ovarian cancer (OvCa) is the sixth most common cancer in women and leading cause of death from gynecologic diseases. Poor prognosis in OvCa is due to late diagnosis and acquired resistance to the commonly used platinum-based regimens. A significant setback for OvCa treatment is the lack of reliable biomarkers and effective targeted therapies. In order to discover novel therapeutic opportunities with approved and emerging drugs for OvCa, we have established primary cultures using ascites or tumor tissue samples from chemo-refractory ovarian cancer patients for ex vivo Drug Sensitivity and Resistance Testing (DSRT) and genomic profiling. In addition, we have performed DSRT with 31 established OvCa cell lines. Comparison of the drug sensitivity profiles of ten primary cancer cell cultures and 31 OvCa cell lines revealed previously unanticipated cancer selective drug vulnerabilities. Several drug groups were identified suggesting that the sensitive samples were addicted to the corresponding signaling networks. For example, in a 53-year old chemorefractory low grade serous OvCa patient, genomic and transcriptomic analyses revealed a fusion gene of NRG-1, a target that was recently reported to involve the NRG1/ERBB3 activation loop in OvCa. We found high expression of ERBB2 and ERBB3 by RNA-seq as well as high levels of phospho-ERBB3, phospho-ERBB2 and phospho-EGFR by immunohistochemistry. In agreement with the molecular mechanism, DSRT analysis identified significant sensitivity of primary cancer cells to EGFR inhibitors, such as erlotinib and to dual EGFR and Her2 inhibitor afatinib. The patient has received combination therapy of gemcitabine and erlotinib during nine months, followed by afatinib monotheraphy that has lead to complete remission after six months treatment. We have detected activated NRG1/ERBB3 activation loop also in several additional ovarian cancer patient cases, highlighting the importance of this signaling pathway in ovarian cancer pathogenesis. Our study reveals that a subset of serous ovarian cancer patients with activating NRG1/ERBB3 signaling loop have clinical benefits from repurposing dual EGFR/Her2 inhibitor afatinib, providing a basis for the clinical use of EGFR and dual EGFR/Her2 tyrosine kinase inhibitors in clinical treatment. In conclusion, DSRT technology together with molecular profiling provides a powerful strategy to identify tumor driver signals and select clinically actionable inhibitors. Hence, this type of systems medicine approach can significantly improve the power of mainly genomics-oriented personalized medicine approaches. Citation Format: Astrid Murumägi, Akira Hirasawa, Suleiman Khan, Daniela Ungureanu, Mariliina Arjama, Teijo Pellinen, Samuli Eldfors, Riitta Koivisto-Korander, Arto Leminen, Ralf Bützow, Tero Aittokallio, Olli Kallioniemi. Identifying ovarian cancer specific targeted drugs using high-throughput drug sensitivity profiles of primary cancer cells [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2017; 2017 Apr 1-5; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2017;77(13 Suppl):Abstract nr 410. doi:10.1158/1538-7445.AM2017-410